S&H names new EVP and director of brand planning

Sudler & Hennessey (S&H) named Paul Giroux as executive vice president and director of brand planning and market analysis. In this new role, Giroux will help coordinate and synchronize the activities and resources of the medical affairs department, the strategic planning group, market research, information services, and the analytics team.
Jim Metropoulos, M.D., co-president of S&H/U.S., stated, "Each of these departments, in its own right, is an exceptional resource that S&H brings to its clients. Collectively, this brand planning group will be a formidable force in the industry."
Giroux joins after six years at Saatchi & Saatchi, where he was strategic marketing director across several brands. Prior to Saatchi, Giroux worked on the client side, as vice president of corporate marketing and business development at Aventis (then RPR).
Louisa Holland, co-president of S&H/U.S. commented, "Paul is a seasoned strategic planner and business analyst, and we're delighted that he'll be joining our group. This unified brand planning and market analysis group will provide the highest level of integrated market analysis to all S&H account teams. "S&H's brand planning team provides strategic solutions to current market challenges and helps to identify future market opportunities for all their clients' brands.
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.